alafenamide

— Based on the results of this study, it is reasonable for HIV clinics to consider including more formal evaluation of tubular damage in routine monitoring urinalyses for patients on TDF. Given ongoing concerns regarding potential nephrotoxicity of TDF and the need for continued nucleotide reverse transcription inhibitors in the backbone of cART regimens, tenofovir alafenamide fumarate (TAF), a new TFV prodrug, was recently FDA approved.